Verona Pharma plc

NasdaqGM:VRNA Stock Report

Market Cap: US$3.1b

Verona Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:VRNA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Nov 24BuyUS$33,300David EbsworthIndividual2,500US$13.32
11 Nov 24SellUS$12,000Mark HahnIndividual300US$40.00
11 Nov 24SellUS$12,000David ZaccardelliIndividual300US$40.00
06 Nov 24BuyUS$198,386Christina AckermannIndividual5,235US$37.90
06 Nov 24BuyUS$188,881David EbsworthIndividual4,920US$38.39
04 Nov 24SellUS$568,387Mark HahnIndividual16,209US$35.10
04 Nov 24SellUS$618,658David ZaccardelliIndividual17,629US$35.13
25 Oct 24SellUS$633,896David ZaccardelliIndividual18,102US$35.02
25 Oct 24SellUS$632,761Mark HahnIndividual18,070US$35.02
22 Oct 24SellUS$2,303,773Mark HahnIndividual525,768US$4.38
22 Oct 24SellUS$2,253,237David ZaccardelliIndividual514,152US$4.39
11 Sep 24SellUS$2,254,080Mark HahnIndividual600,000US$3.76
11 Sep 24SellUS$2,254,320David ZaccardelliIndividual600,000US$3.76
13 Aug 24SellUS$1,275,540Mark HahnIndividual49,800US$26.00
12 Aug 24BuyUS$103,320David EbsworthIndividual4,500US$22.96
12 Aug 24SellUS$5,008Mark HahnIndividual200US$25.04
12 Aug 24SellUS$5,008David ZaccardelliIndividual200US$25.04

Insider Trading Volume

Insider Buying: VRNA insiders have sold more shares than they have bought in the past 3 months.

Ownership Breakdown

What is the ownership structure of VRNA?
Owner TypeNumber of SharesOwnership Percentage
General Public2,424,1652.96%
Individual Insiders3,660,3714.47%
Hedge Funds4,215,9735.15%
VC/PE Firms18,096,32522.1%
Institutions53,434,33565.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 74.81% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.72%
Perceptive Advisors LLC
6,315,933US$240.6m160%4.93%
7.57%
RA Capital Management, L.P.
6,195,639US$236.0m-29.7%2.72%
6.82%
New Enterprise Associates, Inc.
5,584,753US$212.7m0%9.11%
5.15%
Maverick Capital, Ltd.
4,215,973US$160.6m36.3%2.78%
4.62%
OrbiMed Advisors LLC
3,777,778US$143.9m0%1.88%
4.34%
Vivo Capital, LLC
3,549,779US$135.2m-46.3%10.76%
4.14%
Frazier Life Sciences Management, LP
3,383,950US$128.9m2.1%4.86%
3.89%
Deep Track Capital, LP
3,180,025US$121.1m-20.5%3.52%
2.96%
Eventide Asset Management, LLC
2,425,846US$92.4m360%1.51%
2.65%
Federated Hermes, Inc.
2,167,900US$82.6m0.2%0.19%
2.3%
Wellington Management Group LLP
1,878,632US$71.6m19.6%0.01%
2.24%
Octagon Capital Advisors LP
1,835,200US$69.9m-3.17%10.86%
2.13%
Jennison Associates LLC
1,740,886US$66.3m54.3%0.04%
1.86%
David Zaccardelli
1,525,294US$58.1m-1.8%no data
1.76%
Caligan Partners, LP
1,436,878US$54.7m-22.1%16.15%
1.75%
Hood River Capital Management LLC
1,433,934US$54.6m35%0.78%
1.72%
Mark Hahn
1,411,417US$53.8m-1.94%no data
1.63%
T. Rowe Price Group, Inc.
1,335,194US$50.9m40.6%no data
1.49%
Bellevue Asset Management AG
1,220,059US$46.5m7.57%0.52%
1.44%
Citadel Advisors LLC
1,178,022US$44.9m1,050%0.05%
1.43%
Federated Equity Management Company of Pennsylvania
1,173,600US$44.7m0%0.23%
1.36%
Aisling Capital Management LP
1,115,352US$42.5m0%15.85%
1.36%
Loomis Sayles & Company, L.P.
1,111,096US$42.3m0%0.05%
1.27%
Janus Henderson Group plc
1,042,795US$39.7m-4.51%0.01%
1.2%
Rice Hall James & Associates, LLC
985,076US$37.5m4.84%1.9%